Nearly one in 20 people who had a SARS-CoV-2 infection go on to experience myalgic encephalomyelitis/chronic fatigue syndrome ...

Indeed, a recent study published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology found a prolonged ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus's ...

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, sore throat, loss of taste or smell, fatigue and body aches, headache, nausea ...

The COVID-19 outbreak in 2019 triggered measures to raise public awareness regarding pandemics and also led to fast-tracked ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus' ...

The National Institute of Mental Health has awarded a significant grant of $1.5 million to Jianyang Du, PhD, of the ...

A new study published in the Journal of General Internal Medicine, “Incidence and Prevalence of Post‑COVID‑19 Myalgic ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus' ability to invade human cells. SARS-CoV-2 is the virus that spreads COVID-19.

The risk for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is increased following COVID-19, according to study findings.

Researchers have provided the molecular explanation for why some osteoporosis drugs offer protection against COVID-19.